Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

SAGE Therapeutics

5 Disclosed Funding Rounds $1,088,000,000

0 Participating Investments


Therapeutics, Biotechnology, Medical

SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.

Cambridge, Massachusetts, United States, North America (GB)

Organizations in Cambridge in Therapeutics,
Organizations in Cambridge in Biotechnology,
Organizations in Cambridge in Medical,
Organizations in Massachusetts in Therapeutics,
Organizations in Massachusetts in Biotechnology,
Organizations in Massachusetts in Medical,
Organizations in United States in Therapeutics,
Organizations in United States in Biotechnology,
Organizations in United States in Medical,
Organizations in North America in Therapeutics,
Organizations in North America in Biotechnology,
Organizations in North America in Medical

Investors in Cambridge in Therapeutics,
Investors in Cambridge in Biotechnology,
Investors in Cambridge in Medical,
Investors in Massachusetts in Therapeutics,
Investors in Massachusetts in Biotechnology,
Investors in Massachusetts in Medical,
Investors in United States in Therapeutics,
Investors in United States in Biotechnology,
Investors in United States in Medical,
Investors in North America in Therapeutics,
Investors in North America in Biotechnology,
Investors in North America in Medical

Greater Boston Area (0 Investors) (0 Startups), New England (0 Investors) (0 Startups), East Coast (0 Investors) (0 Startups), Northeastern US (0 Investors) (0 Startups)

Founded date 01, 2010

Founders Douglas Covey, Steven Paul

Operating Status Active

Funding Stage IPO

Last Funding Type Post-IPO Equity

Company Type For Profit


Facebook Link

Twitter Link

LinkedIN Link

Wikipedia Link

SAGE Therapeutics is dedicated to the health and well being of patients with central nervous system (CNS) disorders. Their mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers.

Date Round Raised Lead
November, 27, 2020 Post-IPO Equity $650,000,000 Biogen Idec
November, 17, 2017 Post-IPO Equity $345,000,000 -------
March, 13, 2014 Series C $38,000,000 -------
October, 16, 2013 Series B $20,000,000 Third Rock Ventures
October, 18, 2011 Series A $35,000,000 Third Rock Ventures

SAGE Therapeutics Investors (9)

Investor Lead? Round Participating Raise Date Partners
Biogen Idec Yes Post-IPO Equity $650,000,000 November, 27, 2020 -------
ARCH Venture Partners No Series C $38,000,000 March, 13, 2014 -------
Third Rock Ventures No Series C $38,000,000 March, 13, 2014 -------
Foresite Capital No Series C $38,000,000 March, 13, 2014 -------
OrbiMed No Series C $38,000,000 March, 13, 2014 -------
EcoR1 Capital No Series C $38,000,000 March, 13, 2014 -------
Third Rock Ventures Yes Series B $20,000,000 October, 16, 2013 -------
ARCH Venture Partners No Series B $20,000,000 October, 16, 2013 -------
Third Rock Ventures Yes Series A $35,000,000 October, 18, 2011 -------